Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
OA02 - From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment
- 12:00 - 13:00
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Locally Advanced Non-small Cell Lung Cancer
- Moderators:Isabelle Opitz, Luis Paz-Ares
-
+
OA02.03 - Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial
12:02 - 12:12 | Presenter: Marta Casarrubios
- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-065 - Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer
Presenter: Mariano Provencio- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-011 - Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC
Presenter: Andrés Aguilar- Abstract
Loading...
-
+
P1.09 - Global Health, Health Services Research, and Health Economics - Support to Patients and Staff
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Global Health, Health Services Research, and Health Economics - Support to Patients and Staff
-
+
P1.09-03 - Multidisciplinary Thoracic Tumors Board Survey in Spain
Presenter: Bartomeu Massutí- Abstract
Loading...
-
+
P1.15 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
P1.15-09 - First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.
Presenter: Mariano Provencio- Abstract
Loading...
-
+
PL03 - Plenary 3: Presidential Symposium - Top Rated Abstracts (Live Streamed Session)
- 08:30 - 10:20
- 8/08/2022
- Location: Hall C1
- IASLC CME Accredited
- Type: Plenary
- Track: N/A
- Moderators:Heather Wakelee, Eric Lim
-
+
PL03.12 - Progression Free Survival and Overall Survival in NADIM II Study
Presenter: Mariano Provencio- Abstract
Loading...
-
+
MA06 - Resectable and Unresectable Locally Advanced Lung Cancer
- 12:15 - 13:15
- 8/08/2022
- Location: Lehar 1
- Not for CME Credit
- Type: Mini Oral
- Track: Locally Advanced Non-small Cell Lung Cancer
- Moderators:Saulius Cicenas, Celine Mascaux
-
+
MA06.03 - Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
12:17 - 12:22 | Presenter: Atocha Romero
- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- 14:30 - 15:30
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Moderators:Pilar Garrido, António Araújo
-
+
OA15.03 - Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
14:32 - 14:42 | Presenter: Martin Reck
- Abstract
Loading...
